이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

CBD Knee Osteoarthritis Study

2026년 6월 4일 업데이트: Karen Chandler Johnson, University of Tennessee

Pilot Study Using Topical Cannabidiol (CBD) to Manage Osteoarthritic Knee Pain

Osteoarthritis of the knee is a common cause of pain in the US. The currently available medicines for knee osteoarthritis sometimes are not effective at relieving the pain or have unacceptable side effects. Thus, alternate pain relieving treatments are needed.

CBD, an active chemical from the hemp derived cannabis sativa plant, has received a lot of attention for its potential pain relieving properties, but there has been limited research to find out if topically applied CBD can decrease pain from knee osteoarthritis. CBD lacks the psychoactive effects seen with marijuana use, because it does not contain THC which is responsible for those effects in marijuana. It is legal to use CBD in the State of Tennessee (site of study).

The CBD Knee Study is sponsored by the University of Tennessee Health Science Center and is a collaborative effort between doctors at UT and Campbell Clinic. In the CBD Knee Study, the investigators are examining whether topically applied CBD dissolved in Castor Oil will relieve knee pain in persons with knee osteoarthritis.

Persons who take part in the study would need to come for study visits, fill out questionnaires about their health and knee pain, and would be asked to use the topical study oil on their knees. Taking part in the CBD Knee Study is voluntary.

연구 개요

상태

아직 모집하지 않음

정황

상세 설명

Chronic pain is an enormous burden worldwide, impacting more than 30% of the population. Osteoarthritis (OA) is the most common form of joint disfunction and pain, affecting 33 million people in the United States. OA is a prominent cause of pain for older individuals, particularly knee pain. Due to the chronic and progressive nature of OA pain, many patients require long-term analgesic management. Non-steroidal anti-inflammatory drugs (NSAIDs), are commonly used to treat moderate pain from OA, but side effects and numerous potential drug interactions limit use in many individuals. Not surprisingly, opioids became a part of treatment for OA pain in the early 2000s, and have been commonly used for many years even though opioids are not recommend for use by osteoarthritis guideline committees due to their potential risk of misuse, abuse and overdose. With limitations on currently available treatments such as NSAIDs and opioids, the field is now exploring alternative analgesics to manage chronic osteoarthritis pain.

Medical marijuana and cannabis have long been used to treat chronic pain disorders and there is increasing interest to explore cannabinoids as alternate pain therapy. Cannabidiol (CBD), an active cannabinoid from hemp derived cannabis sativa, has garnered attention as a strong pharmaceutical candidate for analgesia. For example, in two recent systematic reviews, CBD was found to be beneficial for treating chronic pain and appeared to improve sleep and Quality of Life (QOL) for persons with chronic pain. CBD lacks the psychoactive effects seen with marijuana use, because it does not contain Δ9- tetrahydrocannabinol (THC) responsible for those effects in marijuana. These properties make CBD a clear candidate for an alternative treatment for chronic pain syndromes such as knee OA.

However, rigorous CBD research is limited in certain chronic pain populations such as persons with OA, but there are some data suggesting benefits. A cross-sectional study, in a large sample of individuals who used oral CBD for arthritis (n=428), showed that 83% reported a reduction in pain following CBD use, and 61% reported a reduction or cessation of other medications, including opioids (18%). There are, however, notable limitations in previous research on CBD for chronic pain that should be acknowledged. Many previous CBD research studies have focused primarily on orally administered CBD often at low doses, which undergoes first-pass metabolism in the liver, reducing bioavailability and potentially diminishing therapeutic effects. Additionally, much of the research relied on the use of over the counter (OTC) CBD products at lower doses, with unverified or untested purity and quality. Thus, additional research on CBD for pain relief is warranted in persons with knee OA. Topical CBD that avoids the first pass metabolism of oral routes has also been shown to reduce chronic pain. In a small randomized clinical trial (n=15) in patients with symptomatic peripheral neuropathy pain, topical CBD Oil use (250 mg / 3 fl. Oz - Higher Dose) resulted in a statistically significant reduction in intense pain, sharp pain and cold/itchy sensations compared with a placebo with no adverse events reported. In another placebo controlled crossover clinical trial in thumb basal joint osteoarthritis, patients had significant reductions in pain after 2 weeks of topical CBD (6.2 mg/ml BID - Lower Dose) administration vs. shea butter (placebo). Another pilot study (n=18) in individuals with hand OA found that topical transdermal CBD gel applied three times daily significantly decreased pain scores (p<0.0001), improved grip strength (p<0.0001), and alleviated stiffness. These findings suggest that topical CBD could represent a promising option for managing chronic localized pain conditions like knee OA. Despite this promising preliminary work, to our knowledge there are no studies using topical CBD at therapeutic doses to treat knee pain in persons with OA to definitively establish efficacy.

There is also a need for a vehicle to deliver the topical CBD dose to the knee area for maximal effect. Castor Oil is an excellent choice. Castor Oil is an odorless vegetable oil made from the seeds of the Castor plant. Castor Oil is already used as a vehicle to assist with delivery of FDA approved topical pain relief medications such as diclofenac sodium (NSAID) to the area of intended use. The main constituent of Castor Oil is ricinoleic acid, which may also have anti-inflammatory and analgesic effects. Thus, Castor Oil is a clear choice as a vehicle to deliver topical CBD to the site of pain in persons with knee OA.

Given healthcare challenges to manage chronic pain, including avoiding opioids because of their addictive potential, investigation of topically applied CBD dissolved in a vehicle such as Castor Oil may provide a promising alternative therapy for the reduction of OA pain of the knee, while having an exceptional safety profile. However, additional research on topical CBD+Castor Oil using rigorous study designs is needed to document efficacy and safety for the treatment of OA pain of the knee.

To address this issue, the investigators will conduct a pilot randomized crossover clinical trial to examine the analgesic efficacy of topical CBD+Castor Oil compared to a topical Castor Oil alone. 30 patients with OA pain of the knee will be randomized. The investigators anticipate 60 patients will sign consent and screen to randomize 30 patients.

SPECIFIC AIMS

Aim 1: Examine medication analgesic efficacy within subjects (n=30) in a balanced crossover design where each participant receives both treatments in randomized order with a 2-week washout period in between. Participants will be randomized to (1) CBD+Castor Oil followed by Castor Oil alone; or 2) Castor Oil alone followed by CBD+Castor Oil. Each oil will be used for a total of 1 month. Hypothesis 1: CBD+Castor Oil will have reduced knee pain scores compare to Castor Oil alone.

Aim 2: Examine changes in knee function, sleep, and knee Quality Of Life (QOL) by medication condition. Hypothesis 2: CBD+Castor Oil will have higher knee function, reduced sleep disturbance scores, and higher QOL than Castor Oil alone.

The investigators hypothesize that with adequate analgesic properties and low safety concerns, topical CBD+Castor Oil may be extremely useful to manage chronic OA knee pain while improving knee function, QOL, and sleep.

연구 유형

중재적

등록 (추정된)

30

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Tennessee
      • Memphis, Tennessee, 미국, 38163
        • University of Tennessee Health Science Center
        • 수석 연구원:
          • Karen C Johnson, MD, MPH
        • 수석 연구원:
          • Karen Derefinko, PhD
        • 부수사관:
          • William Mihalko, MD, PhD
        • 부수사관:
          • Phyllis Richey, PhD
        • 부수사관:
          • Fridtjof Thomas, PhD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. Knee OA (grade 2-3 as measured by the Kellgren-Lawrence Classification)
  2. OA knee pain on the Visual Analog Pain Scale > 4 in either knee
  3. Receiving treatment at one of the eight Campbell Clinic Orthopaedics locations

Exclusion Criteria:

  1. Other forms of arthritis such as psoriatic arthritis or rheumatoid arthritis due to different sources of inflammation in these conditions
  2. Allergies to CBD or Castor Oil
  3. Current opioid use
  4. BMI of over 40
  5. Those who cannot walk without an assistance device (e.g., walker)
  6. Those who are currently on knee injections (i.e. cortisol or hyaluronic acid gel) for knee pain
  7. Patients scheduled for a knee replacement in the next 3-6 months
  8. Active cannabis or CBD use
  9. Alcohol consumption > 21 alcoholic drinks each week
  10. Active pregnancy, nursing, or actively planning a pregnancy
  11. Active chronic liver or renal disease
  12. Active depression/suicidality
  13. Medications that interact with CBD in the liver that cannot be discontinued 14. Discretion of the Multiple Principal Investigators for concerns regarding noncompliance with the study intervention.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: CBD+Castol Oil
250 mg CBD dissolved in 1 ml of Castor Oil to be applied topically to the knee BID
250 mg of CBD will be dissolved in 1 ml of Castor Oil. Participants will use 1ml of this solution on each knee BID
위약 비교기: Castor Oil Alone
1 ml of Castor Oil Alone applied topically to the knee as the placebo comparator BID
1 ml of Castor oil alone will be applied to each knee BID as the placebo

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Knee Pain
기간: Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit

The investigators will use ecological momentary assessment to collect knee pain scores and develop pain trajectories. A Visual Analog Scale of Self-Reported Pain will be assessed at study visits and up to once a day via text message using the Wong-Baker visual analogue scale. A score of 0 is no pain and a score of 10 is severe pain. Please note this is crossover clinical trial and there are 2 Baseline Visits (One and Two).

Knee Pain will be assessed at the Screening Visit as an eligibility criteria and at Baseline One Visit (Day 1), Follow-up One Visit (Day 30), Baseline Two Visit (Day 44), and Follow-up Two Visit (Day 74). The Baseline One Visit will occur 2 weeks after the Screening Visit.

Change in knee pain scores on the Visual Analog Scale of Self-Reported Pain will be assessed from the Baseline One Visit to the the Follow-up One Visit and from the Baseline Two Visit to the the Follow-up Two Visit.

Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit

2차 결과 측정

결과 측정
측정값 설명
기간
Sleep
기간: Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit
The PROMIS (Patient-Reported Outcomes Information System) Sleep Questionnaire will be used to assess sleep disturbance and sleep related impairment over the past 7 days. The questionnaire is divided into two distinct short-form assessments: 1) PROMIS Sleep Disturbance and 2) PROMIS Sleep-Related Impairment. The PROMIS sleep questionnaire utilizes a standardized T-score metric where the general U.S. population average is 50, with a standard deviation of 10. Higher scores indicate a greater severity of the concept being measured (e.g., more sleep disturbance or more sleep-related impairment). Below 55 is within normal limits, 55-59.9 is mild, 60-69.9 is moderate, and 70 and above is severe. Please note this is crossover clinical trial and there are 2 Baseline Visits (One and Two). Sleep will be assessed at the Baseline One Visit (Day 1), Follow-up One Visit (Day 30), Baseline Two Visit (Day 44), and Follow-up Two Visit (Day 74).
Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit
Knee Related Quality of Life and Function
기간: Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit

The Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire will be used to assess five knee dimensions: pain, symptoms, activities of daily living (ADL), sport and recreation function, and knee-related quality of life. Each dimension is scored from 0 to 100, with 0 indicating extreme problems and 100 indicating no problems.

Please note this is crossover clinical trial and there are 2 Baseline Visits (One and Two). Knee Related Quality of Life and Function as measured by the KOOS questionnaire will be assessed at the Baseline One Visit (Day 1), Follow-up One Visit (Day 30), Baseline Two Visit (Day 44), and Follow-up Two Visit (Day 74). The Baseline One Visit will occur 2 weeks after the Screening Visit. The Follow-up One Visit will occur 1 month after the Baseline One Visit. The Baseline Two Visit will occur 2 weeks after the Follow-up One Visit. The Follow-up Two Visit will occur 1 month after the Baseline Two Visit.

Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit

기타 결과 측정

결과 측정
측정값 설명
기간
Adherence with Study Medication
기간: Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit

The investigators will measure adherence with study medication by weighing the study medication bottles at study visits to determine the number of dosage units used from the bottle during medication periods. This weighing method has been used to assess adherence in other topical medication trials.

Please note this is crossover clinical trial and there are 2 Baseline Visits (One and Two). Bottle weighing to measure adherence with study medication will be assessed at the Baseline One Visit (Day 1), Follow-up One Visit (Day 30), Baseline Two Visit (Day 44), and Follow-up Two Visit (Day 74).

The number of dose units used from the Baseline One Visit to the the Follow-up One Visit will be assessed and the number of dose units used from the Baseline Two Visit to the the Follow-up Two Visit will be assessed.

Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit
Adherence with Study Medication by Self-report
기간: From enrollment at Day 1 to the end of treatment at Day 74
The investigators will also assess adherence with study medication by self-report via text message during medication use weeks up to 60 times between the Baseline One Visit (Day 1) and Follow-up Two Visit (Day 74). The investigators will use a simple question to ask the participant whether the study oil was placed on the Right Knee (Yes/No) and the Left Knee (Yes/No) today. This measure will be used to encourage compliance with the Study Intervention.
From enrollment at Day 1 to the end of treatment at Day 74

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Karen C Johnson, MD, MPH, University of Tennessee

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 7월 1일

기본 완료 (추정된)

2028년 3월 20일

연구 완료 (추정된)

2028년 3월 30일

연구 등록 날짜

최초 제출

2026년 5월 29일

QC 기준을 충족하는 최초 제출

2026년 6월 4일

처음 게시됨 (실제)

2026년 6월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 6월 10일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 6월 4일

마지막으로 확인됨

2026년 4월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

The study will prepare and distribute a dataset. Confidentiality of individual participants will be maintained with all releases of data. The final study analytical database will be processed according to HIPAA definitions for public data sharing. During this process, the participant data will be de-identified by using processes which include but are not limited to: removal of identifiers, translation of dates and ages to delta time values, and assignment of random study identifiers. Out of this process will be a series of de-identified data files representing the final analytical data set. These data files will be provided in a standard format that is readable across a variety of applications and operating system platforms. Documentation that will be provided along with the data sharing file that may include but is not limited to: data dictionary, data code book, valid variable ranges, the protocol, MOP, and any electronic versions of any paper forms that were used in data collection.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다